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Background and Objectives. Our previous research devel-
oped two statistical models that are useful indicators of
current (ON-model) or recently discontinued (OFF-mod-
el) recombinant human erythropoietin (rHuEPO) use by
athletes. The component variables of the ON-model are
hematocrit (Hct), reticulocyte hematocrit (RetHct), serum
erythropoietin (EPO), percent macrocytes (%Macro), and
soluble transferrin receptor (sTfr), whilst the OFF-model
uses only the first three variables. Genetics and training
modalities of elite athletes may conceivably produce
unusual values for blood parameters related to erythro-
poiesis. The aims of this study were to develop reference
ranges in elite athletes for key hematologic parameters
as well as ON- and OFF-models scores, and to evaluate
the effect of ethnicity, gender, residence at moderate
altitude (~2000 m) and within-individual variation on the
variables and model scores.
Design and Methods. Over a period of three weeks, 413
female and 739 male elite athletes from 12 countries vis-
ited laboratories to provide three blood samples for
analysis of blood parameters sensitive to erythropoiesis.
For each parameter and for the ON- and OFF-model
scores, we used mixed modeling to establish the range
within which we could be 95% certain that the value for
a randomly chosen athlete would fall, taking into account
various random effects (variation within and between
subjects and laboratories) and fixed effects (means for
different levels of ethnicity, age, sport, altitude of resi-
dency). We performed similar analyses for changes in
the ON- and OFF-model scores between the three visits.
Results. Most fixed effects were accompanied by clear-
cut, small to moderate differences in several parame-
ters. However, residency at moderate altitude was accom-
panied by a much higher hematocrit than residency near-
er sea level, with the mean (and 95% confidence limits)
for the difference being 2.3 (0.9 to 3.7) and 1.8 (0.1 to
3.5) units for males and females, respectively. Males at
altitude also demonstrated a moderately higher ON-mod-
el score. Otherwise the influence of these effects was
small for ON-, OFF- and changes in model scores.
Although the International Olympic Commit-tee (IOC) officially prohibited the use ofrecombinant human erythropoietin (rHuEPO)
in 1990, its detection is complicated by the fact
that erythropoietin (EPO) occurs naturally in the
body. In 2000, Lasne and de Ceaurriz demonstrat-
ed that the isoform pattern of rHuEPO in urine was
quite different to that of endogenous erythropoi-
etin.1 At the same time, we demonstrated that a
statistical model using five blood parameters, which
are altered substantially during and after a period
of rHuEPO administration, was capable of discrim-
inating between subjects administered either rHuE-
PO or placebo.2 This blood test, in combination with
the urine test, was approved and implemented by
the IOC for use during the Sydney 2000 Olympic
Games.
Our approach using the blood matrix established
two statistical models. The ON-model, indicative of
accelerated erythropoiesis, was developed to dis-
criminate between current rHuEPO users and place-
bo subjects using the component variables hemat-
ocrit (Hct), reticulocyte hematocrit (RetHct), per-
cent macrocytes (%Macro), serum EPO concentra-
tion and serum soluble transferrin receptor (sTfr)
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Interpretation and Conclusions. Assessment of an ath-
lete’s blood parameters and ON- and OFF-model scores
may need adjustment for training modalities and other
characteristics of the subject. Changes in model scores
(together with monitoring of urine samples for the pres-
ence of rHuEPO) provide a promising approach to detec-
tion of rHuEPO abuse, because they are less sensitive to
subject characteristics and less variable than raw model
scores.
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concentration.2 The OFF-model, which relies on indi-
cators of depressed erythropoiesis (abnormally low
RetHct and EPO) juxtaposed with high Hct, was
developed to identify subjects who had recently
stopped receiving rHuEPO. In addition, because of
the marked acceleration in erythropoiesis during the
early stages of rHuEPO use, and the decrease in ery-
thropoiesis after cessation of use, there is a resul-
tant variation in ON- and OFF-model scores as a
function of time. We propose that changes in these
model scores could be another potentially useful
indicator of rHuEPO use.
However the erythropoietic-dependent parame-
ters included in our models could potentially be con-
founded by numerous factors. These include biolog-
ical factors such as disease,3-6 physiologic factors
such as exercise,7 environmental factors such as
altitude exposure8 and also the biological variation
of blood parameters over time.9,10 Consequently
identifying rHuEPO users amongst the elite athlete
population will entail differentiating between the
fluctuations associated with exposure to such influ-
ences, and the atypical variation of hematologic
parameters caused by rHuEPO use.
Although numerous large-scale studies of blood
parameters have been performed with athletes11-15
we could not locate any conducted on athletes from
multiple countries which also reported each of the
five parameters included in our model. Therefore, in
order to extend our previous research, which
demonstrated that the erythropoietic changes asso-
ciated with rHuEPO use were repeatable and con-
sistent across different ethnic groups, we sought to
quantify the reference ranges for these hematolog-
ic parameters under different training, environmen-
tal and physiologic circumstances. We anticipate
that generating these reference ranges within an
athlete population will assist readers to better
appreciate the discriminative power of hematolog-
ic parameters to highlight rHuEPO use, and also pro-
vide a reference source for institutions who collect
and analyze blood samples from athletes.
Our research group undertook a large-scale, inter-
national blood profiling study of elite athletes and
this paper presents data on two important goals.
First, our aim was to develop 95% reference ranges
(the range within which we could be 95% certain
that the value for a randomly chosen athlete would
fall) in elite athletes for our component hemato-
logic parameters (as well as ON- and OFF-model
scores). Second, we sought to quantify the effects
of gender, ethnicity, exercise, sporting discipline,
altitude as well as biological and analyzer variation
on the hematologic variables and detection models.
Design and Methods
Subjects
There were 1152 (739 males, 413 females)
state/national level athletes from 12 countries
recruited as volunteers to provide blood samples
(Table 1). All athletes signed statements of informed
consent, and completed a detailed case report form
regarding factors such as: sport, ethnic group,
tobacco use, injury or illness, iron and other dietary
supplementation. Athletes were classified into one
of the four major ethnic groups: Caucasian, Asian,
African or Oceanian (subjects with mixed ethnic
background were noted). The experimental proce-
dure was approved by the Ethics Committee of the
Australian Institute of Sport in accordance with the
Helsinki Declaration.
Suitability for inclusion in the study was based on
three criteria (age, performance level and drug his-
tory). Athletes included in the study were required
to be at least 14 years of age at the commence-
ment of the study, and had to have competed at
state/regional level (or higher) during the previous
12 months. Athletes were excluded from the study
if they reported that they had received a blood
transfusion during the previous month, or if they
admitted taking growth hormone, insulin-like
growth factor, erythropoietin or any substance
known to enhance red blood cell formation during
the previous two months. All information was gath-
ered by questionnaire but there was no expedient
means to verify whether athletes answered truth-
fully.
Study design
Three venous blood samples were collected from
each athlete over an extended period (day 1, days 3-
9 and days 10-21). The day and time of blood col-
lection were recorded in each case, together with
the time elapsed since the athlete had last exer-
cised. At the end of the study, athletes completed
the final section of a case report form which
detailed any injury, illness, variations in medication,
alterations in living altitude or other relevant
changes that had occurred during the study period.
In 32 cases (0.01%) the day of collection was not
recorded, and in a total of 66 cases (0.02%) the
sample was collected outside the specified day
range, though seldom by more than two days. In
some cases, only one (n=140, 0.04%) or two (n=162,
0.05%) blood samples were collected from an ath-
lete due to logistical reasons. In 100 cases (0.03%)
whole blood samples were analyzed but not serum
measures, whilst in 40 cases (0.01%) serum assays
were performed but whole blood analyses were
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incomplete, so that different numbers of observa-
tions were available for different variables.
Blood collection and analysis
All blood was collected by trained phlebotomists
and was sampled from an antecubital vein after five
minutes of supine rest. To minimize inter-group
variation, the collection procedures at all sites were
standardized (a detailed protocol for collection and
processing of the blood and serum was sent to each
institution participating in the study). Samples were
drawn into one 8 mL serum separation tube with
clot activator (Vacuette, Greiner Labortechnik,
Frikenhaussen Germany) and two 2 mL K3EDTA
tubes (Vacuette, Greiner Labortechnik). All blood
collection tubes, cryogenic vials and other items
required for the study were purchased in Australia
and transported to each location (with the excep-
tion of Norway and Italy).
Erythrocyte and reticulocyte parameters were
analyzed using the ADVIA 120 Hematology Analyz-
er (Bayer Diagnostics, Tarrytown, NY, USA) which
performs flow cytometric measurements. When pos-
sible, analysis was completed within 8 hr of collec-
tion. A total of 13 ADVIAs located in 11 countries
(two each in France and Italy) were used during the
study. Each ADVIA was calibrated against appropri-
ate reference materials, and controlled daily using
Bayer ADVIA TESTpoint Haematology Low, Normal
and High controls and Bayer ADVIA TESTpoint Retic-
ulocyte Low and High controls. The average coeffi-
cient of variation (CV) for the parameters used in the
models (or those used to derive the parameters)
analyzed on all the ADVIAs were as follows: Hct
2.0%; percent reticulocytes (%Retic) 11%; mean cell
volume of reticulocytes (MCVr) 1.6%; red blood cell
count (RBC) 1.6%; mean cell volume (MCV) 1.3%;
hemoglobin concentration (Hb) 1.4%. The relative-
ly high CV for reticulocytes (the range for all labo-
ratories was 3.6-17.5%) was due to high values
recorded in two laboratories that had no previous
experience with reticulocyte analysis prior to our
study. All serum samples were separated and
aliquoted into cryotubes as previously described,2
stored at –20°C or –80°C, packed on dry-ice, then
shipped to Australia for analysis. The EPO and sTfr
concentrations were determined using an automat-
ed solid-phase chemiluminescent immunoassay
(Diagnostic Products Corporation, Los Angeles, CA,
USA) and an automated immunonephelometric
assay (Dade Behring, Germany), respectively. The
automated immunoassays for EPO and sTfr were
controlled using three and two levels of controls,
respectively. Using three levels of EPO controls
(mean 15.2, 30.4 and 62.3 mU/mL), the within-assay
CVs were 4.7, 7.1 and 5.1%, and between-assay CVs
were 7.3, 7.2 and 9.5% respectively. Using two lev-
els of sTfr controls (mean 0.63 and 1.45 mg/L), the
within-assay CVs were <1.0% and 2.2%, and
between-assay CVs were 3.4 and 2.8%, respective-
ly. Ferritin concentration was measured on the first
serum sample collected from each athlete using a
single Hitachi 911 Biochemistry Analyzer (Roche
Diagnostics, Rotkreuz, Switzerland). The mean CV
for ferritin assays throughout the study was 5.5%
over the range of 15-500 ng/mL.
A blood sample from each subject was screened
for hemoglobinopathies using a Bio-Rad Variant
Analyzer (Bio-Rad, Hercules, California, USA) and a
Variant Beta-Thalassemia Short Program Kit (Bio-
Rad, Hercules, California, USA). This enables detec-
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Table 1. Ethnicity and sport group of international athletes.
Ethnicity Country of residence during study Male Female
(n) (n)
Caucasian Australia, France, Italy, Mexico, New Zealand,
Norway, South Africa, USA 378 242
Asian China, Malaysia, Singapore 221 126
African Kenya, South Africa 87 27
Oceanian Australia, New Zealand 19 7
Other 34 11
Totals 739 413
Group Sporting Category Example Male Female
(n) (n)
1 Esthetic sports Gymnastics, 11 19
Synchronized swimming, Diving
2 Athletics Track and Field 65 27
3 Combat Sports Boxing, Wrestling, Judo, Karate, 149 58
Fencing, Taekwondo
4 Endurance Sports Marathon running; Cycling, 84 41
Orienteering; Triathlon, 
Nordic Ski
5 Multiple Modern pentathlon, Decathlon, 6 1
Heptathlon, Biathlon
6 Power Sports Weightlifting, Athletic field events 36 13
such as hammer, discus
7 Power/ Endurance Rowing, Canoeing, Swimming, 133 84
Track cycling
8 Racquet Sports Tennis, Badminton, Squash 33 20
9 Skill Sports Table tennis, Shooting, Archery 16 14
10 Team Ball Games Basketball, Netball, Volleyball, 201 136
Hockey, Soccer
11 Not stated 5 0
Athletes self-identified to which ethnic group they belonged. Caucasian includes
European, North African, South West Asian, Arabian, Persian and Indians; Asian
includes Chinese, Korean, Japanese, Siberian, American Indian and Eskimos;
African includes both Central and South Africans; Oceanian refers to Australian
Aboriginals, Melanesians and Polynesians; Other includes those who did not
state their ethnic background or athletes of mixed ethnic background.
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tion and quantification of hemoglobins A, A2, F, S
and E. For hemoglobinopathy screening, the between
assay CV for HbA2 and HbF quantification was estab-
lished using two control levels for each. For HbA2
levels 2.6% and 5.3% the CV was 6.9% and 4.9%,
respectively; for HbF levels 1.8% and 9.1% the CV
was 10.9% and 2.9%, respectively.
For reference, the models that will be used are
those previously published.2
ON-model score = 3.721Hct + 30.45RetHct +
0.1871loge(EPO) + 0.1269loge(sTfr) + 0.1115loge
(%macrocytes + 0.1)
OFF-model score = 6.149Hct – 92.87RetHct –
0.1463loge (EPO)
Statistical analysis
Estimating reference ranges for hematologic para-
meters and model scores. For each of the hemato-
logical parameters and model scores, means, stan-
dard deviations and 95% reference ranges (defined
herein as the range within which we could be 95%
certain that the value for a randomly chosen athlete
would fall, taking into account various random and
fixed effects) were estimated using the mixed mod-
eling procedure (Proc Mixed) in the Statistical
Analysis System (SAS Version 8.1, SAS Institute,
Cary, NC, USA). The fixed effects were ethnicity,
sport, altitude, age, visit, time since last exercise,
and time of day of the visit. Levels of some of these
effects were chosen in an iterative process of analy-
sis to identify those for which there was a substan-
tial difference and for which there was a reasonable
number of athletes on each level. The levels for the
first three fixed effects are shown in the tables,
whilst data for the remaining fixed effects have
been included in a comprehensive online appendix.
While a small number of athletes in other loca-
tions recorded their residence during the study as
being at moderate altitude, the majority resided in
Kenya, Mexico, South Africa and the USA, and the
effect of altitude was evaluated as a comparison
between these four nations (altitude) and all of the
others (non-altitude). For sport the only comparison
we considered was that between endurance (groups
4 and 7 in Table 1) and non-endurance.
The first visit of the sub-group of athletes with the
following characteristics was nominated as the ref-
erence group: Caucasian, non-endurance athletes
of age 19-24 years, who resided less than 610 m
above sea level, and whose blood sample was col-
lected between 07:30AM and 4:00PM at least 12
hours after exercise. The levels chosen for the ref-
erence group were those with the largest number of
athletes. To avoid possible confusion with reference
ranges, this group is subsequently referred to as the
modal group. Findings for other levels of the fixed
effects are expressed as departures from this modal
group. The use of a different instrument to analyze
the blood of athletes in each country and the analy-
sis of three blood samples from each athlete per-
mitted estimation of between- and within-instru-
ment variation as well as between- and within-ath-
lete variation. Although beyond the scope of the
current paper, a comprehensive account of the sta-
tistical procedures used and the results obtained are
included in the online appendix.
Transformations. The reference ranges are based
on the assumption that the different values of the
parameter for different athletes are normally dis-
tributed. The distributions of the raw values of sev-
eral parameters were highly skewed, so these para-
meters were transformed appropriately. Square-root
transformations were used for RetHct, reticulocyte
count and %Retics, while log transformations were
used for EPO, and sTfr. The transformation of macro-
cyte counts was log(count + 0.1), to accommodate
observations with zero counts.
Changes in model scores over time. Changes in the
ON- and OFF-model scores were comprehensively
analyzed for the subgroup of 995 athletes (366
females and 629 males) who had at least two visits
(see online appendix for details of the statistical
approach and results). The data reported here are
mean and standard deviations, as well as 95% ref-
erence ranges, for changes in the modal group on
their first two laboratory visits within 2 hours of the
same time of day, with an unknown change in time
since exercise, and with 7-8 days between visits.
Results
Subject demographics
Athletes have been categorized into groups of
similar training/motor skill basis (Table 1), and these
athletes trained on average for 3.3 hours per day. For
statistical purposes, endurance was a combination
of endurance sport and power/endurance categories
(217 males, 125 females in total). Two hundred and
forty of the athletes who trained/resided at moder-
ate altitude (~1730–2220 m) were permanent res-
idents, whilst 48 resided temporarily for the dura-
tion of the study. Around 6.7% of the athletes were
current smokers (55 males, 22 females) whilst an
additional 2.7% (26 males, 5 females) had smoked
at some time previously. Approximately 18% of the
athletes stated that they had taken oral creatine
supplementation or some form of iron supplemen-
tation either during or in the four weeks prior to the
study.
Reference ranges of erythropoietic markers in athletes 
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Many of the blood parameter values differed sub-
stantially between males and females, consequent-
ly reference ranges were estimated separately for
each sex. For brevity, only data for various groups
and effects that were substantially different (greater
than 0.2 standard deviations)17 from those of the
modal group have been highlighted and discussed.
Interpretation of reference ranges
The reference ranges in Table 2 for groups other
than the modal group are appropriate for individu-
als who differ only by a single category from the
modal group, for example if they are a different eth-
nic group, or perform a different sport, or reside at
altitude. For an athlete exposed to multiple effects,
the appropriate reference range can be estimated
using the approach illustrated in the online appen-
dix.
Reference ranges for hematologic
parameters
The span of the 95% reference range for Hct was
of similar magnitude for females and males, whilst
the mean Hct value for males exceeded the mean
female value by 4.5 points. The largest effect on Hct
values, consistent across gender, was due to alti-
tude; residing at a moderate altitude of ~1730-
2220 m was associated with an average increase of
1.8-2.3 Hct points.
Serum EPO levels were comparable between
females and males (Table 2). The highest value
recorded in a female was 83.3 mU/mL from an iron-
deficient athlete (serum ferritin 4.4 ng/mL, Hct 0.30).
The two highest serum EPO values recorded in males
were 81.9 and 75.6 mU/mL.
The effect of ethnicity on sTfr levels was modest
with appreciable differences between all four eth-
nic groups and both sexes (Table 2). Although the
span of the 95% reference range was similar in all
groups, the upper range for African and Asian ath-
letes was higher than in Caucasians (for both males
and females). The small sample size of our Ocean-
ian athlete group makes extrapolation from our data
tenuous for this group. Although not included in the
K. Sharpe et al.
Table 2. 95% reference ranges, means and standard deviations for the five component hematologic and serum parameters, as
well as ON- and OFF-model scores, for the modal group (Caucasian non-endurance athletes aged 19-24 years, measured <610
m above sea level on their first laboratory visit between 07:30 and 16:00 at least 12 h after exercise). Reference ranges for
other groups are shown only when they are substantially different from those of the modal group.
Females Hematocrit (%) Reticulocyte hematocrit (%) Macrocytesa (%) EPOb (mU/L) sTfrb (mg/L) ON-model score OFF-model score
Range - Modal group 34.3–45.0 0.30–1.08 0.0–1.9 4.4–23.5 0.76–2.02 1.63–2.42 1.01–2.01
Mean (SD) 39.6 ( 2.6) 0.79 ( 0.12) 0.29 (*2.24) 10.1 (*1.53) 1.24  (*1.28) 2.03 (0.19) 1.51 (0.25)
Ethnicity
Asian 0.83–2.21
African 33.4–44.5 0.34–1.20 0.93–2.53 0.85–1.88
Oceanian 0.0–1.1 3.6–21.0 0.65–1.84 1.47–2.30
Sport
Endurance 35.3–46.1 0.0–2.5 1.68–2.47 1.08–2.08
Altitude
1730 to 2220 m 35.9–46.8 0.36–1.20 0.0–1.1 0.80–2.14
Males Hematocrit (%) Reticulocyte hematocrit (%) Macrocytes (%) EPO (mU/ml) sTfr (mg/L) ON-model score OFF-model score
Range - Modal group 38.8–49.6 0.31–1.12 0.0–1.1 4.6–18.6 0.81–1.87 1.78–2.51 1.24–2.24
Mean (SD) 44.2 (2.7) 0.81 (0.12) 0.21 (*1.97) 9.2 (*1.43) 1.23 (*1.24) 2.14 (0.18) 1.74 (0.25)
Ethnicity
Asian 39.4–50.3 0.85–1.95 1.83–2.56
African 0.87–2.03
Oceanian 0.35–1.21 0.89–2.09
Sport
Endurance 0.0–1.4 5.1–20.8 0.84–1.94 1.84–2.56
Altitude
1730 to 2220 m 41.0–52.0 0.42–1.34 0.0–0.8 4.9–20.0 0.89–2.05 1.91–2.65
aMean macrocyte percent shown is the back-transformed mean of the log-transformed value. bData shown are for the square root of the value provided by the instrument.
*Standard deviations are multiplicative factors that are applied to this mean (see online appendix for explanatory details).
detection models, ferritin concentration was mea-
sured to confirm iron deficiency anemia in cases in
which Hct and/or Hb were low. Nineteen female and
13 male athletes had serum ferritin values under 10
and 20 ng/mL, respectively. The highest ferritin val-
ues were 694 and 1154 ng/mL; the lower score was
for a male athlete who had a previously diagnosed
disorder of hereditary spherocytosis. We also col-
lected and have reported further hematologic para-
meters (hemoglobin concentration, red cell count,
mean cell volume), as well as reticulocyte charac-
teristics (absolute count and percentages, mean cell
volume of reticulocytes) and readers interested in
these data are directed to the online appendix.
Reference ranges for the ON-model
The width of the 95% reference ranges for both
males and females was comparable, whilst mean
scores were higher for males than females (Table 2).
The effects of ethnicity, age, sport, time since exer-
cise or time of day were neither marked nor consis-
tent between sexes (data reported in online appen-
dix). The largest single effect was due to altitude,
which increased ON-model scores in males by an
average of 0.14. The influence of this effect was not
evident in female athletes. Both male and female
athletes who were categorized as endurance ath-
letes demonstrated ON-model scores that were
0.05-0.06 higher than those of non-endurance ath-
letes. The 95% reference range for males in the
modal group was 1.78-2.51. There were nine males
who recorded an ON-model score greater than 2.80,
and a further three who recorded ON-model scores
of 3.00 or more (3.01, 3.06 and 3.32). The (Cen-
tral/Southern African) athlete who had the highest
score presented with low leukocyte (2.2×109/L) and
platelet (100×109/L) counts, suggesting the pres-
ence of a significant abnormality. Unfortunately our
attempts to follow-up this result failed due to our
inability to locate the athlete. By comparison, all 26
male recreational athletes injected with rHuEPO in
trials held in Sydney and Beijing reached ON-mod-
el scores of greater than 2.88 by the end of the 4-
week period of rHuEPO administration, and 72%
exceeded a score of 3.00 at some time during the
four weeks.2 For females in the modal group the
95% reference range was 1.63-2.42, with a maxi-
mum score of 2.76 recorded in one athlete. By com-
parison, in the Sydney and Beijing rHuEPO admin-
istration trials, all 15 females injected with rHuEPO
attained an ON-model score of more than 2.54 by
the end of the 4-week period of rHuEPO adminis-
tration, and 80% exceeded a score of 2.76 at some
time during the four weeks.2
Reference ranges for the OFF-model
The width of the 95% reference ranges for both
males and females was comparable, with mean
scores higher for males than females. The influence
of effects, including ethnicity, age, sport, altitude,
time of day or time since exercise, was not consis-
tent across sexes. The largest effect was due to eth-
nicity, with female African athletes demonstrating
OFF-scores on average 0.14 lower than the modal
group. This effect was not evident in male African
athletes. An effect attributable to endurance sport
was evident in female athletes (scores 0.07 higher)
but not their male counterparts.
For males in the modal group the 95% reference
range was 1.24-2.24, with a maximum score of 2.55
recorded in one athlete. In the Sydney and Beijing
administration trials, 92% of the males who were
injected with rHuEPO reached OFF-model scores
greater than 2.24 at some stage after their last
injection. The 95% reference range for females in
the modal group was 1.01-2.01, with a maximum
score of 2.12 recorded in one athlete. Every female
injected with rHuEPO during the Sydney and Beijing
trials exceeded an OFF-model score of 2.01 at some
stage after rHuEPO administration ceased.
Changes in the ON- and OFF-model scores
over time
The mean (±SD) changes in ON-model scores over
a 7-8 day period in the modal group were 0.00±0.12
and 0.02±0.14 for males and females, respectively.
The largest change in ON-model scores over this
time period was –0.43 (95% reference range –0.25
to 0.24) for males and –0.52 (95% reference range
–0.26 to 0.29) for females (the negative sign indi-
cates that the change was a decrease over time).
The mean (±SD) changes in OFF-model scores over
a 7-8 day period in the modal group were –0.10±
0.18 and –0.05±0.22 for males and females,  respec-
tively. The largest change in OFF-model score was
1.21 (95% reference range –0.45 to 0.26) for males
and –0.93 (95% reference range –0.48 to 0.39) for
females.
Incidence of hematologic abnormalities
Only one of the 21 male athletes with demon-
strable hematologic abnormalities had an ON-mod-
el score that was higher than the upper 95% refer-
ence limit of 2.51. This athlete had a known abnor-
mality (hereditary spherocytosis) and gave a score of
3.01. ON-model scores for all 19 of the female ath-
letes with demonstrable haematological abnormal-
ities fell within the 95% reference range. None of
these 40 athletes produced OFF-model scores
greater than the upper limit of the 95% reference
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range, whilst 11 athletes had OFF-model scores that
were below the lower limit. The effects of hemato-
logic abnormalities on the component variables and
model scores will be reported in detail in a separate
manuscript.
Discussion
The major findings of this study were that in a
large cohort of international elite athletes, we iden-
tified a small number of athletes with ON-model
scores that were considerably in excess of the
expected range. This implies that if an athlete is
found to possess a high ON-model score, further
evidence (such as the presence of rHuEPO in the
urine) is required to establish whether or not the
athlete used rHuEPO. However the observed distri-
bution of OFF- and CHANGE-model scores suggests
that these models may, by themselves, be extreme-
ly useful tools for identifying athletes who have
recently ceased using rHuEPO.
Fluctuations in hematologic parameters
associated with extraneous factors
With the goal of providing a framework within
which to judge the merit of using our indirect blood
tests to detect rHuEPO use, we estimated the vari-
ation in our component parameters caused by cir-
cumstances potentially encountered by elite ath-
letes. Such factors may need to be considered and
included when setting threshold/decision limits for
individual athletes. The main factors considered in
the analysis of our data were ethnicity, whether the
athlete participated in an endurance sport, and res-
idence at altitude.
Residence at a moderate altitude (~1730–2220
m) was by far the most consistent effect, with the
largest influence on blood parameters. There was an
increase in Hct, RetHct, EPO and sTfr in the altitude
sub-group (males and females). Numerous publica-
tions have described an increase in red blood cell
count (RBC), mean cell volume (MCV), Hct, Hb and
%Retic in people living at altitude compared with
those at sea level: among the most comprehensive
was the classic study of Hurtado et al.18 The greater
change in Hb (9.1%, data reported in the online
appendix) than Hct (3.9%) is consistent with dehy-
dration at altitude compared with sea level, and an
acute decrease in plasma volume of ~7-10% is a
well recognized response of lowlanders traversing to
~2000m.19 Our Hct versus Hb data suggest that this
acute effect might also be a chronic effect for alti-
tude residents. When the plasma volume shift was
estimated from changes in the Hct and Hb,20 plas-
ma volume was reduced for the altitude sub-group
by 8.0% in males and 8.8% in females. Therefore,
the confounding effect of plasma volume shifts
needs to be taken into account for blood testing
conducted at altitude, or after a training block con-
ducted at altitude. The time course for parameters
to normalize following exposure to altitudes of
~2000m therefore needs to be addressed for the
detection models. Our group has investigated groups
of athletes following acute and chronic exposure to
various altitudes, and these data will be presented
in a separate manuscript.
In our sample cohort, the effect of endurance on
Hct was negligible for males but was 1.1 Hct points
higher for females. Further, Hb was higher for both
males and females than for their non-endurance
counterparts (complete data set reported in online
appendix). The difference noted in our study asso-
ciated with endurance athletes was of a compara-
ble magnitude, but opposite, to that found by Schu-
macher et al.,21 who reported that in a cohort of 426
endurance and 321 mixed and power male athletes,
endurance athletes tended to have Hb 5 g/L-1 low-
er than their non-endurance counterparts. Schu-
macher et al. noted that their protocol was unable
to discern the acute effects of exercise (since their
samples were taken after two days of reduced sport-
ing activity). However, their finding that endurance
training does not substantially influence Hct/Hb
compared with that in sedentary subjects, together
with our data showing no further influence whether
or not samples were drawn within four hours of
exercise, suggests that any hemodilution associat-
ed with endurance exercise is unlikely to affect
Hct/Hb markedly.
When the concomitant influence of altitude was
removed, male and female African athletes in our
cohort possessed marginally lower Hb than their
Caucasian counterparts. This is consistent with pre-
vious research that has reported that Blacks possess
Hb levels ~5 g/L lower than Whites.22 This effect
was discernible in lower Hct scores for the female
athletes but not males, which underlined the rela-
tively minor magnitude of this specific influence.
Ethnicity was also found to consistently influence
sTfr levels. Both male and female athletes in the
Asian and African groups possessed higher sTfr val-
ues than their Caucasian counterparts. Allen et al.
reported previously that in a cohort of 225 healthy
adults, subjects they classified as Blacks possessed
sTfr levels ~9% higher than subjects classified as
either Caucasian, Asian or Hispanic.23 In contrast to
our study, they reported no statistical difference
between sTfr levels in Asians and Caucasians. It was
difficult to extrapolate from the increased (males)
and decreased (females) sTfr levels encountered in
1254
haematologica vol. 87(12):december 2002
K. Sharpe et al.
our Oceanian cohort due to the limited sample size.
All serum measurements were performed in the
same laboratory, and it is difficult to find an expla-
nation for observed differences in sTfr levels
between ethnic groups.
The potential for hematologic abnormalities to
affect blood parameters and therefore confound the
detection models was also considered. Although
there were 40 athletes in which hematologic abnor-
malities could be demonstrated, only one subject
(male) with hereditary spherocytosis had blood
parameters sufficiently disturbed to result in an ON-
model score (3.01) far above the relevant upper 95%
reference limit. None of the 40 athletes registered
OFF-model scores outside the 95% reference limit.
Nevertheless, we recommend that an athlete with a
model score outside the reference range should be
investigated for the presence of a clinical/medical
abnormality. We conclude that the overall robust-
ness of our hematologic parameters supports their
utility as potential tools to identify athletes abus-
ing rHuEPO.
Detection of rHuEPO users
Various approaches have been considered to iden-
tify athletes abusing rHuEPO, the simplest of these
using a single blood parameter such as Hct or %Ret-
ic. Given the proximity of the upper limit of our Hct
and %Retic reference ranges to the cut-off thresh-
olds, we estimate about 1 in 40 male athletes (or 1
in 10 if residing at ~2000 m) risk failing the 50% Hct
rule, and about 1 in 100 male athletes residing at
moderate altitude risk failing the 2.4% reticulocyte
threshold. For females the chance of exceeding the
47% Hct cut-off is less, but still around 1 in 40 for
female athletes who live/train at moderate altitude.
Additional detail is provided in Table 3.
An alternative approach is to use scores obtained
from a combination of blood parameters, with cut-
offs chosen to achieve an acceptable balance
between sensitivity and specificity. This approach
has the advantage of requiring that there be a con-
sistent profile of altered erythropoeisis before an
athlete is suspected of drug use, rather than relying
on an unusual value for a single parameter. The abil-
ity of the multiple-parameter algorithms to predict
rHuEPO use in athletes is illustrated by a simple
comparison between the upper limits of the refer-
ence ranges obtained in our current study, with the
scores elicted by subjects injected with rHuEPO in
our previous research.2 The maximum upper limit of
the reference range for ON-model scores (for males,
living/training < 610 m) was calculated to be 2.62
(the peak score associated with Asian, endurance
athletes). In our previous administration trials con-
ducted in Sydney and Beijing, all of the males giv-
en rHuEPO injections recorded ON-model scores in
excess of 2.88 towards the end of the 25-day
administration period. The corresponding maximum
upper reference range limit for the ON-model in
female athletes is 2.47. All of the females injected
with rHuEPO in our Sydney and Beijing trials record-
ed scores in excess of 2.54, and 14 of the 15 record-
ed scores in excess of 2.65.
Whilst this discrimination confirms the usefulness
of the model for predicting rHuEPO use in athletes,
our current study showed that some hematologic
conditions, such as hereditary spherocytosis, can
also lead to elevated ON-model scores. Further,
there were a number of outliers within the elite ath-
lete population with ON-model scores well in excess
of the 95% reference range. Since the athletes
declared that they were not taking rHuEPO and they
could not be excluded from the study on medical
grounds, the concomitant presence of outliers and
the possibility of hematologic abnormalities makes
using a single ON-model score by itself tenuous.
Authorities may elect to use a higher reference
range to achieve 100% specificity based on our cur-
rent results, but only at the cost of an almost com-
plete loss of sensitivity in the ON-model.
For OFF-model scores the maximum upper limit of
the 95% reference ranges was calculated to be 2.24
for males and 2.08 for females (Table 2). In the Syd-
ney and Beijing administration trials, 21 of the 26
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Table 3. Percentage of 1,152 athletes (739 males, 413
females) from 12 countries in the profiling study with blood
parameters equal to or greater than the specified value.
Samples were collected on the first visit to the laboratory
and measured on an ADVIA analyzer.
Females Males
% %
Hematocrit (%)
44.0 15 73
47.0 1.2 32
50.0 0.0 5.4
53.0 0.0 0.3
Hemoglobin (g/L-1)
155 5.1 48
165 0.7 16
175 0.0 2.9
185 0.0 0.4
Reticulocyte percentage (%)
2.0 10 9.4
2.4 1.7 3.4
2.8 0.7 1.4
males injected with rHuEPO recorded OFF-model
scores in excess of 2.50, whilst 14 of the 15 females
recorded scores in excess of 2.10. Consistent with
our discovery of athletes with unusual ON-model
scores, there were also a number of outliers within
our elite athlete sample who demonstrated unusu-
al OFF-model scores. However, whereas the unusu-
al ON-model scores depicted accelerated erythro-
poiesis and therefore could have been confused with
an individual using rHuEPO, the unusual OFF-mod-
el scores were lower than the 95% reference range
and therefore would not have been confused with
an athlete who had recently ceased using rHuEPO.
Furthermore, none of the hematologic abnormal-
ities led to elevated OFF-model scores. The absence
of outliers with very high OFF-model scores sug-
gests that the OFF-model, by itself, is an extremely
useful tool to identify athletes who have recently
ceased using rHuEPO.  It is pertinent to note that
using an appropriate cut-off score based on popu-
lation data, we have never observed a false positive
result using the OFF-model. Hence this approach
provides a level of assurance not evident with sin-
gle parameter models. We believe that the benefits
of the OFF-model include its robustness in identify-
ing athletes who should be followed-up as part of
a targeted testing program to detect rHuEPO users.
Change in model scores over time
When we examined the stability of CHANGE
scores in the multiple blood samples we collected
over the three-week period, ON-model scores
appeared to be more stable than OFF-model scores.
The average change in the ON-model was close to
zero whereas OFF-model scores showed a minor
decrease over the three visits; these changes reflect
the relative contributions of Hct and RetHct to the
two model scores [see the online appendix
(http://www.haematologica.org/2002_12/1248.htm
#appendix for a comprehensive evaluation of this
trend]. However the stability of the model scores
(particularly ON-model) for an individual over time
has sufficient potential for highlighting rHuEPO use
to warrant further research. Specifically, when
applied in unison with the iso-electric focusing tech-
nique for detecting rHuEPO in urine, this could lever-
age the efficacy of out-of-competition testing for
rHuEPO where both blood and urine samples are col-
lected. We reached this conclusion because several
studies have shown that athletes who stop taking
rHuEPO more than four weeks prior to competition
lose any competitive advantage,2,24 which implies
that athletes must continue to use rHuEPO in the
weeks immediately before competition. Athletes tak-
ing rHuEPO who are tested in this time window will
tend to have a relatively high ON-model score, but
may not fail the urine test if their previous injection
was more than 3 days earlier. If the athlete contin-
ued taking rHuEPO up until the time of competition
it would heighten the likelihood of a subsequent
urine sample revealing the presence of rHuEPO.
Alternatively, if the athlete elected to minimize
the risk of failing a second doping control test by
discontinuing rHuEPO use, our previous data sug-
gests there will be a significant drop in ON-model
score for the second blood sample.2 This would pro-
duce a large change in ON-model score, and if the
magnitude of the CHANGE score was suspicious it
could perhaps offer antidoping authorities justifi-
cation to pursue subsequent monitoring of the ath-
lete. Further, it should be noted that the ON- and
OFF-models considered here were developed to dis-
criminate between rHuEPO users and placebo sub-
jects, but (as yet unrealised) alternate models may
be more appropriate for detecting intra-athlete
changes in erythropoiesis. 
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What is already known on this topic
A blood-based method to detect surreptitious use of
recombinant human erythropoietin (r-HuEPO) was
approved and implemented for the Sydney 2000
Olympic games. It is based on hematologic and bio-
chemical parameters that, in combination, allow recent
abuse of r-HuEPO to be detected.
What this study adds
To assess cases of potential abuse of r-HuEPO in com-
petitive athletes, it is essential to rely on robust reference
ranges for the hematologic and biochemical parame-
ters. In addition, the effect of altitude training needs to
be taken into account. This report provides reference
ranges for several hematologic and biochemical para-
meters that are used to assess r-HuEPO abuse.  It pro-
vides additional validation of the approach used for the
Sydney Olympic games
Potential implications for clinical practice
This study reinforces the notion that  a combination of
hematologic and biochemical parameters is effective in
identifying recent or past abuse of r-HuEPO in competi-
tive athletes.
Carlo Brugnara, Deputy Editor
(Boston, USA)
